학술논문
Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial
Document Type
Article
Author
Hillmen, Peter; Boucher, Rebecca H.; Webster, Nichola; Dalal, Surita; Brock, Kristian; Yates, Francesca; Sankhalpara, Chhaya; Macdonald, Donald; Fegan, Christopher; McCaig, Alison; Schuh, Anna; Pettitt, Andrew; Gribben, John G.; Patten, Piers; Devereux, Stephen; Bloor, Adrian; Fox, Christopher P; Forconi, Francesco; Rawstron, Andrew; Hillmen, Peter
Source
Blood; November 2020, Vol. 136 Issue: 1, Number 1 Supplement 1 p17-18, 2p
Subject
Language
ISSN
00064971; 15280020
Abstract
Background:The Blood Cancer UK TAP CLARITY trial for relapsed or refractory CLL combined IBR with VEN in order to eradicate detectable disease with a plan to stop therapy early if measurable residual disease (MRD) <0.01% (MRD4) was achieved in the peripheral blood (PB) and bone marrow (BM).